Developer docs
API playgroundTry for free, no card

Search company profiles

TiumBio

Full company profile

uuid0004mxl

Namestring
TiumBio
Legal namestring
(주)티움바이오
Websiteurl
tiumbio.com
Company typeenum
Public
Founded yearint
2016
Descriptiontext

TiumBio (티움바이오), founded in 2016 and listed on KOSDAQ (ticker 321550) in 2019, is a clinical-stage Korean biopharmaceutical company developing novel therapeutics for rare and incurable diseases. Its pipeline is built on two proprietary platforms — a synthetic small molecule (NCE) platform and a biologic (NBP) platform — yielding four core assets: TU2218 (Tosposertib), a first-in-class TGF-β/VEGF dual inhibitor in Phase 1b/2a for head and neck cancer with positive ASCO 2026 combination data alongside Keytruda (75% response rate, 10.9-month median PFS in 1L patients); TU2670 (Merigolix), a best-in-class oral GnRH antagonist in Phase 2 for endometriosis and uterine fibroids (Phase 2a primary endpoint met May 2024); TU7710, a bypassing factor biologic for hemophilia A patients with neutralizing antibodies in Phase 1; and TU7918, a long-acting Factor IX therapy for hemophilia B. The company owns 67 patents and has secured International Nonproprietary Names for both lead candidates.

The business model is a licensing-and-co-development GTM rather than direct commercialization. TiumBio out-licenses territorial rights and engages in clinical combination collaborations with global pharmaceutical partners — MSD (Merck) for the Keytruda combination, BeiGene for the tislelizumab combination, Chiesi (2018 out-license), Hansoh Pharma (China rights to Merigolix, including ART expansion), and Daewon Pharmaceutical (Korea rights). Revenue is therefore composed of upfront payments, development and regulatory milestones, royalties, and Korean government grants (KDDF, Ministry of Health and Welfare, Ministry of SMEs and Startups, KIPO). The company is not yet generating product revenue. CEO Hun-taek Kim (PhD, Texas A&M; MBA, USC), credited with developing Korea's first recombinant hemophilia protein and prior FDA/EMA-approved drugs, leads the company with a ~30.56% ownership stake. As of Q1 2026, TiumBio held approximately 125B KRW in near-cash assets and 301B KRW in total FVPL financial assets, with an ongoing FDA Breakthrough Therapy Designation application preparation for Tosposertib serving as the primary near-term catalyst.

Short descriptiontext

TiumBio is a clinical-stage Korean biopharmaceutical company developing novel therapeutics for rare and incurable diseases — including TGF-β/VEGF dual inhibitors, oral GnRH antagonists, and hemophilia biologics — monetized via global out-licensing and co-development partnerships with MSD, Chiesi, Hansoh, BeiGene, and Daewon.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeongnam, South Korea
HQ citystring
Seongnam
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immuno-oncology drugs, rare disease therapeutics, TGF-beta inhibitors, GnRH antagonists, hemophilia treatments
Industry2 codes
PRIMARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Medicinal Chemicals & Botanical Products2833
Product category
Rare Disease Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing / License-out Revenue
TypeLicensing Royalties
Description

TiumBio generates revenue through licensing agreements with global pharmaceutical companies for its pipeline assets. Revenue includes upfront payments, milestone payments tied to development and regulatory achievements, and royalties on product sales. Notable license-outs include TU2218 to Chiesi (2018) and TU2670 to Hansoh Pharma and Daewon Pharmaceutical.

tiumbio.com
2Government Research Grants
TypeOthers
Description

The company receives government funding from Korean agencies including KDDF (Korea Drug Development Fund), the Ministry of Health and Welfare, the Ministry of SMEs and Startups, and the Korean Intellectual Property Office to support pipeline R&D.

tiumbio.com
3Equity Financing
TypeOthers
Description

As a pre-commercial biopharma, TiumBio relies on equity raises including KOSDAQ IPO (2019), Series C (400B KRW, 2019), Series B (235B KRW, 2018), and Series A (120B KRW, 2017). The company is not yet generating product revenue.

tiumbio.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

TiumBio is a clinical-stage biopharmaceutical company that discovers and develops novel therapeutics for rare and intractable diseases through two proprietary platforms: a synthetic small molecule (NCE) platform and a biologic (NBP) platform. Its four clinical-stage assets are TU2218 (Tosposertib, dual TGF-β/VEGF inhibitor for immuno-oncology and fibrosis), TU2670 (Merigolix, oral GnRH antagonist for endometriosis and uterine fibroids), TU7710 (bypassing factor biologic for hemophilia A with inhibitors), and TU7918 (long-acting Factor IX for hemophilia B). The company is pre-commercial and monetizes its pipeline through global out-licensing, co-development collaborations, and milestone/royalty arrangements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 1L mPFS 10.9 months (vs. ~3.6 months for standard Keytruda monotherapy, ~5.5 months for Keytruda+chemo)
+3 more records
Product overview1 text field

TiumBio is a clinical-stage biopharmaceutical company developing a pipeline of novel drugs for rare and incurable diseases. The portfolio consists of four main drug candidates: TU2218 (Tosposertib) is a dual TGF-β/VEGF inhibitor being developed as an immuno-oncology drug and for fibrosis; TU2670 (Merigolix) is an oral GnRH antagonist for endometriosis and uterine fibroids; TU7710 is a bypassing agent biologic for hemophilia patients with neutralizing antibodies; and TU7918 is a long-acting B-type hemophilia treatment. The company operates in both synthetic small molecule drugs and biologics, with a strategy focused on rare diseases with high unmet medical needs.

Product and service4 records
1TU2218 (Tosposertib)
CategoryImmuno-oncology / TGF-β inhibitor
Description

Oral dual TGF-β/VEGF inhibitor being developed as an immuno-oncology agent and anti-fibrotic treatment. The dual mechanism simultaneously targets cancer cell proliferation and the immunosuppressive tumor microenvironment, and is being evaluated in combination with anti-PD-1 antibodies for recurrent/metastatic head & neck squamous cell carcinoma.

2TU2670 (Merigolix)
CategoryWomen's health / GnRH antagonist
Description

Oral gonadotropin-releasing hormone (GnRH) antagonist being developed for the treatment of endometriosis and uterine fibroids. Designed to offer a best-in-class profile with improved safety and efficacy over existing injectable GnRH agonists and other oral GnRH antagonists.

3TU7710
CategoryRare hematology / Bypassing factor
Description

Bypassing agent biologic therapy for hemophilia A patients who have developed neutralizing antibodies to standard factor replacement therapy, with extended half-life designed to reduce infusion frequency.

4TU7918
Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Hansoh Pharma (한소제약)
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-11-01
Description

Hansoh Pharma obtained China clinical Phase 1 approval for Merigolix (TU2670, HS-10518) in November 2023. Hansoh is also pursuing ART (Assisted Reproductive Technology) indications for the compound, with clinical trial approvals expanding the development scope. TiumBio receives milestone payments and royalties.

tiumbio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-02-01
Description

BeiGene signed a clinical collaboration with TiumBio in February 2022 to evaluate TU2218 with tislelizumab (BeiGene's anti-PD-1 antibody) in combination therapy for cancer treatment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

MSD and TiumBio signed a joint clinical collaboration agreement in 2022 to evaluate TU2218 (Tosposertib) in combination with MSD's Keytruda (pembrolizumab) for the treatment of recurrent/metastatic head and neck squamous cell carcinoma. The ongoing Phase 1b/2a clinical trial is evaluating safety and efficacy of the combination therapy.

4Daewon Pharmaceutical (대원제약)
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-01-01
Description

Technology transfer of Merigolix (TU2670) to Daewon Pharmaceutical in 2022 for the Korean market. Daewon successfully completed Phase 2 clinical trial for uterine fibroids, achieving the primary endpoint of statistically significant reduction in heavy menstrual bleeding.

tiumbio.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

TiumBio entered a strategic partnership with SK Plasma through a capital increase participation in 2021, forming a strategic business relationship in the Korean biopharmaceutical sector.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

TiumBio established Protium Science as a subsidiary in 2021 (classified as a CDAO - Contract Development and Manufacturing Organization) to support internal drug development capabilities and potentially provide services.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2018-01-01
Description

In 2018, TiumBio out-licensed TU2218 (NCE401) for the treatment of lung disease to global pharmaceutical company Chiesi. This represented one of the company's major global licensing achievements prior to refocusing on oncology indications.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Established Korean pharmaceutical company with a broad drug development pipeline including novel small molecules and biologics. Comparable as a Korea-based pharma with similar therapeutic area exposure, though operating at significantly larger scale.

TypeDirect peer
Description

Chinese biopharmaceutical company with both small molecule (Tyvyt/PD-1) and biologic drug development platforms. Comparable to TiumBio's dual NCE+NBP platform strategy and similarly pursues global pharma collaborations.

3Hansoh Pharma
TypeDirect peer
Description

Chinese pharmaceutical company and TiumBio's licensee for Merigolix (TU2670/HS-10518) in China. Comparable as a clinical-stage partner advancing the same women's health asset, providing a relevant proxy for development pace and regulatory execution in the China market.

TypeBroad incumbent
Description

Global pharmaceutical leader and TiumBio's clinical collaboration partner for Keytruda+TU2218 combination in head and neck cancer. Comparable as the dominant IO player whose strategy and commercial priorities shape the value ceiling of TiumBio's combination programs.

TypeDirect peer
Description

China-based clinical-stage biopharmaceutical company developing therapeutics in oncology, viral hepatitis, and metabolic diseases. Comparable to TiumBio as an Asia-based clinical-stage biotech pursuing global out-licensing with similar therapeutic area breadth.

6Hutchmed
TypeDirect peer
Description

China-based clinical-stage biopharmaceutical company focused on oncology drug discovery and development. Comparable to TiumBio as an Asia-based clinical-stage oncology biotech pursuing global out-licensing deals with multinational pharma partners.

TypeBroad incumbent
Description

Korean pharmaceutical company with an extensive pipeline of novel small molecules and biologics. Comparable to TiumBio in therapeutic area focus and Korean clinical-stage development model, but with broader pipeline scope and commercial revenue.

TypeBroad incumbent
Description

Major China-headquartered global oncology company and TiumBio's clinical collaboration partner for tislelizumab+TU2218 combination. Comparable as an oncology-focused company with PD-1 IO franchise, providing context on combination partnership economics.

TypeDirect peer
Description

Korean clinical-stage biotechnology company developing antibody-drug conjugates and biologics platforms. Comparable to TiumBio as a Korean clinical-stage biotech leveraging proprietary biologic discovery platforms and out-licensing models.

TypeRegional player
Description

Korean pharmaceutical company developing therapeutics across oncology, women's health, and rare diseases. Comparable to TiumBio in therapeutic area overlap and Korean market focus, though with more mature commercial operations.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TiumBio

Rare Disease Therapeuticstiumbio.com

TiumBio is a clinical-stage Korean biopharmaceutical company developing novel therapeutics for rare and incurable diseases — including TGF-β/VEGF dual inhibitors, oral GnRH antagonists, and hemophilia biologics — monetized via global out-licensing and co-development partnerships with MSD, Chiesi, Hansoh, BeiGene, and Daewon.

What TiumBio does

TiumBio (티움바이오), founded in 2016 and listed on KOSDAQ (ticker 321550) in 2019, is a clinical-stage Korean biopharmaceutical company developing novel therapeutics for rare and incurable diseases. Its pipeline is built on two proprietary platforms — a synthetic small molecule (NCE) platform and a biologic (NBP) platform — yielding four core assets: TU2218 (Tosposertib), a first-in-class TGF-β/VEGF dual inhibitor in Phase 1b/2a for head and neck cancer with positive ASCO 2026 combination data alongside Keytruda (75% response rate, 10.9-month median PFS in 1L patients); TU2670 (Merigolix), a best-in-class oral GnRH antagonist in Phase 2 for endometriosis and uterine fibroids (Phase 2a primary endpoint met May 2024); TU7710, a bypassing factor biologic for hemophilia A patients with neutralizing antibodies in Phase 1; and TU7918, a long-acting Factor IX therapy for hemophilia B. The company owns 67 patents and has secured International Nonproprietary Names for both lead candidates.

The business model is a licensing-and-co-development GTM rather than direct commercialization. TiumBio out-licenses territorial rights and engages in clinical combination collaborations with global pharmaceutical partners — MSD (Merck) for the Keytruda combination, BeiGene for the tislelizumab combination, Chiesi (2018 out-license), Hansoh Pharma (China rights to Merigolix, including ART expansion), and Daewon Pharmaceutical (Korea rights). Revenue is therefore composed of upfront payments, development and regulatory milestones, royalties, and Korean government grants (KDDF, Ministry of Health and Welfare, Ministry of SMEs and Startups, KIPO). The company is not yet generating product revenue. CEO Hun-taek Kim (PhD, Texas A&M; MBA, USC), credited with developing Korea's first recombinant hemophilia protein and prior FDA/EMA-approved drugs, leads the company with a ~30.56% ownership stake. As of Q1 2026, TiumBio held approximately 125B KRW in near-cash assets and 301B KRW in total FVPL financial assets, with an ongoing FDA Breakthrough Therapy Designation application preparation for Tosposertib serving as the primary near-term catalyst.

TiumBio firmographics

Firmographics
Name
TiumBio
Legal name
(주)티움바이오
Website
https://tiumbio.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
TiumBio is a clinical-stage Korean biopharmaceutical company developing novel therapeutics for rare and incurable diseases — including TGF-β/VEGF dual inhibitors, oral GnRH antagonists, and hemophilia biologics — monetized via global out-licensing and co-development partnerships with MSD, Chiesi, Hansoh, BeiGene, and Daewon.
Ownership category
akta.pro rank

TiumBio industry classification

Industry
Product category
Rare Disease Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Immuno-oncology drugs
  • Rare disease therapeutics
  • TGF-beta inhibitors
  • GnRH antagonists
  • Hemophilia treatments

Where TiumBio is headquartered

Location

Headquarters

HQ city
Seongnam
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

TiumBio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Technology Licensing / License-out Revenue: TiumBio generates revenue through licensing agreements with global pharmaceutical companies for its pipeline assets. Revenue includes upfront payments, milestone payments tied to development and regulatory achievements, and royalties on product sales. Notable license-outs include TU2218 to Chiesi (2018) and TU2670 to Hansoh Pharma and Daewon Pharmaceutical.
  2. Government Research Grants: The company receives government funding from Korean agencies including KDDF (Korea Drug Development Fund), the Ministry of Health and Welfare, the Ministry of SMEs and Startups, and the Korean Intellectual Property Office to support pipeline R&D.
  3. Equity Financing: As a pre-commercial biopharma, TiumBio relies on equity raises including KOSDAQ IPO (2019), Series C (400B KRW, 2019), Series B (235B KRW, 2018), and Series A (120B KRW, 2017). The company is not yet generating product revenue.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

TiumBio product offering

Product offering

Core offering

TiumBio is a clinical-stage biopharmaceutical company that discovers and develops novel therapeutics for rare and intractable diseases through two proprietary platforms: a synthetic small molecule (NCE) platform and a biologic (NBP) platform. Its four clinical-stage assets are TU2218 (Tosposertib, dual TGF-β/VEGF inhibitor for immuno-oncology and fibrosis), TU2670 (Merigolix, oral GnRH antagonist for endometriosis and uterine fibroids), TU7710 (bypassing factor biologic for hemophilia A with inhibitors), and TU7918 (long-acting Factor IX for hemophilia B). The company is pre-commercial and monetizes its pipeline through global out-licensing, co-development collaborations, and milestone/royalty arrangements.

Product overview

TiumBio is a clinical-stage biopharmaceutical company developing a pipeline of novel drugs for rare and incurable diseases. The portfolio consists of four main drug candidates: TU2218 (Tosposertib) is a dual TGF-β/VEGF inhibitor being developed as an immuno-oncology drug and for fibrosis; TU2670 (Merigolix) is an oral GnRH antagonist for endometriosis and uterine fibroids; TU7710 is a bypassing agent biologic for hemophilia patients with neutralizing antibodies; and TU7918 is a long-acting B-type hemophilia treatment. The company operates in both synthetic small molecule drugs and biologics, with a strategy focused on rare diseases with high unmet medical needs.

Differentiator

Problem solved

Functional benefit

Products and services

  • TU2218 (Tosposertib) Oral dual TGF-β/VEGF inhibitor being developed as an immuno-oncology agent and anti-fibrotic treatment. The dual mechanism simultaneously targets cancer cell proliferation and the immunosuppressive tumor microenvironment, and is being evaluated in combination with anti-PD-1 antibodies for recurrent/metastatic head & neck squamous cell carcinoma.
  • TU2670 (Merigolix) Oral gonadotropin-releasing hormone (GnRH) antagonist being developed for the treatment of endometriosis and uterine fibroids. Designed to offer a best-in-class profile with improved safety and efficacy over existing injectable GnRH agonists and other oral GnRH antagonists.
  • TU7710 Bypassing agent biologic therapy for hemophilia A patients who have developed neutralizing antibodies to standard factor replacement therapy, with extended half-life designed to reduce infusion frequency.
  • TU7918

Quantifiable outcome

  • 1L mPFS 10.9 months (vs. ~3.6 months for standard Keytruda monotherapy, ~5.5 months for Keytruda+chemo)
  • +3 more outcomes

Companies that use TiumBio

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles1 record

TiumBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

TiumBio partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Hansoh Pharma (한소제약)coreOEM/ Whitelabel/ Licensing Partner · 1 November 2023Hansoh Pharma obtained China clinical Phase 1 approval for Merigolix (TU2670, HS-10518) in November 2023. Hansoh is also pursuing ART (Assisted Reproductive Technology) indications for the compound, with clinical trial approvals expanding the development scope. TiumBio receives milestone payments and royalties.
  • BeiGenecoreStrategic or Co-development Partner · 1 February 2022BeiGene signed a clinical collaboration with TiumBio in February 2022 to evaluate TU2218 with tislelizumab (BeiGene's anti-PD-1 antibody) in combination therapy for cancer treatment.
  • MSD (Merck & Co.)coreStrategic or Co-development Partner · 1 January 2022MSD and TiumBio signed a joint clinical collaboration agreement in 2022 to evaluate TU2218 (Tosposertib) in combination with MSD's Keytruda (pembrolizumab) for the treatment of recurrent/metastatic head and neck squamous cell carcinoma. The ongoing Phase 1b/2a clinical trial is evaluating safety and efficacy of the combination therapy.
  • Daewon Pharmaceutical (대원제약)coreOEM/ Whitelabel/ Licensing Partner · 1 January 2022Technology transfer of Merigolix (TU2670) to Daewon Pharmaceutical in 2022 for the Korean market. Daewon successfully completed Phase 2 clinical trial for uterine fibroids, achieving the primary endpoint of statistically significant reduction in heavy menstrual bleeding.
  • SK Plasma (SK플라즈마)minorStrategic or Co-development Partner · 1 January 2021TiumBio entered a strategic partnership with SK Plasma through a capital increase participation in 2021, forming a strategic business relationship in the Korean biopharmaceutical sector.
  • Protium Science (프로티움 사이언스)coreStrategic or Co-development Partner · 1 January 2021TiumBio established Protium Science as a subsidiary in 2021 (classified as a CDAO - Contract Development and Manufacturing Organization) to support internal drug development capabilities and potentially provide services.
  • ChiesicoreOEM/ Whitelabel/ Licensing Partner · 1 January 2018In 2018, TiumBio out-licensed TU2218 (NCE401) for the treatment of lung disease to global pharmaceutical company Chiesi. This represented one of the company's major global licensing achievements prior to refocusing on oncology indications.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

TiumBio competitors and assessment

Company assessment

Broad incumbents

  • Yuhan Corporation: Established Korean pharmaceutical company with a broad drug development pipeline including novel small molecules and biologics. Comparable as a Korea-based pharma with similar therapeutic area exposure, though operating at significantly larger scale.
  • MSD (Merck & Co.): Global pharmaceutical leader and TiumBio's clinical collaboration partner for Keytruda+TU2218 combination in head and neck cancer. Comparable as the dominant IO player whose strategy and commercial priorities shape the value ceiling of TiumBio's combination programs.
  • Hanmi Pharmaceutical: Korean pharmaceutical company with an extensive pipeline of novel small molecules and biologics. Comparable to TiumBio in therapeutic area focus and Korean clinical-stage development model, but with broader pipeline scope and commercial revenue.
  • BeiGene: Major China-headquartered global oncology company and TiumBio's clinical collaboration partner for tislelizumab+TU2218 combination. Comparable as an oncology-focused company with PD-1 IO franchise, providing context on combination partnership economics.

Direct peers

  • Innovent Biologics: Chinese biopharmaceutical company with both small molecule (Tyvyt/PD-1) and biologic drug development platforms. Comparable to TiumBio's dual NCE+NBP platform strategy and similarly pursues global pharma collaborations.
  • Hansoh Pharma: Chinese pharmaceutical company and TiumBio's licensee for Merigolix (TU2670/HS-10518) in China. Comparable as a clinical-stage partner advancing the same women's health asset, providing a relevant proxy for development pace and regulatory execution in the China market.
  • Ascletis Pharma: China-based clinical-stage biopharmaceutical company developing therapeutics in oncology, viral hepatitis, and metabolic diseases. Comparable to TiumBio as an Asia-based clinical-stage biotech pursuing global out-licensing with similar therapeutic area breadth.
  • Hutchmed: China-based clinical-stage biopharmaceutical company focused on oncology drug discovery and development. Comparable to TiumBio as an Asia-based clinical-stage oncology biotech pursuing global out-licensing deals with multinational pharma partners.
  • LegoChem Biosciences: Korean clinical-stage biotechnology company developing antibody-drug conjugates and biologics platforms. Comparable to TiumBio as a Korean clinical-stage biotech leveraging proprietary biologic discovery platforms and out-licensing models.

Regional players

  • JW Pharmaceutical: Korean pharmaceutical company developing therapeutics across oncology, women's health, and rare diseases. Comparable to TiumBio in therapeutic area overlap and Korean market focus, though with more mature commercial operations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

TiumBio social profiles

Digital presence

TiumBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TiumBio leadership team

Management profile

Number of profiles

Profiles7 records

TiumBio subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

TiumBio funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TiumBio M&A and investment

M&A and investment

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TiumBio

What does TiumBio do?

TiumBio is a clinical-stage biopharmaceutical company that discovers and develops novel therapeutics for rare and intractable diseases through two proprietary platforms: a synthetic small molecule (NCE) platform and a biologic (NBP) platform. Its four clinical-stage assets are TU2218 (Tosposertib, dual TGF-β/VEGF inhibitor for immuno-oncology and fibrosis), TU2670 (Merigolix, oral GnRH antagonist for endometriosis and uterine fibroids), TU7710 (bypassing factor biologic for hemophilia A with inhibitors), and TU7918 (long-acting Factor IX for hemophilia B). The company is pre-commercial and monetizes its pipeline through global out-licensing, co-development collaborations, and milestone/royalty arrangements.

Is TiumBio a public or private company?

TiumBio is a public company. It is classified as public and is currently operating.

When was TiumBio founded?

TiumBio was founded in 2016. It employs 11 to 50 people.

Where is TiumBio based?

TiumBio is headquartered in Seongnam, South Korea, in the Asia region.

How does TiumBio make money?

Three revenue lines are on record. Technology Licensing / License-out Revenue is the primary driver. The others are government Research Grants and equity Financing.

Who are TiumBio's main competitors?

Broad incumbents on record are Yuhan Corporation, MSD (Merck & Co.), Hanmi Pharmaceutical and BeiGene. Direct peers are Innovent Biologics, Hansoh Pharma, Ascletis Pharma, Hutchmed and LegoChem Biosciences. JW Pharmaceutical is listed as a regional player.

Does TiumBio have an API?

No public API is recorded for TiumBio.

What industry is TiumBio in?

TiumBio's product category is Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIACAI, Hematology Specialty Pharmaceuticals (Non-malignant), with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingTiumBio grants 70,000 stock options at KRW 4,530 per shareTiumBio granted 70,000 stock options at KRW 4,530 per share, with vesting over 2–4 years and exercise from Sept. 30, 2028 to Sept. 29, 2033. Recipients include Park Eun-kyung (50,000) and Scott Kim (20,000), raising total outstanding options to 1,041,988. The per-option fair value was KRW 3,446.90.The future of tradingTiumBio cuts 2023 stock option grant to 124,000 shares after employee departuresTiumBio revised its March 29, 2023 stock option grant, cutting recipients from 14 to 13 and shares from 127,000 to 124,000 due to employee departures. The revised grant leaves 1,041,988 total options outstanding, with an exercise price of KRW 9,810 and a window from March 29, 2025 to March 28, 2030.NateCombination therapy with immune checkpoint inhibitors receives US patent... Tium Bio up 12% [Featured Stock]: Nate NewsTiom Bio's stock rose 12% after the US patent for its immune-oncology candidate Tosporcept (TU2218) in combination therapy was granted. The patent covers combination with major immune checkpoint inhibitors and Lenvatinib, with rights extending to July 2042. The company said the patent solidifies IP for its Phase 2a clinical trial with Keytruda.AijournTiumBio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First-Line R/M HNSCC at ASCO 2026TiumBio presented Phase 2a interim clinical data at ASCO 2026 for Tosposertib (TU2218) combined with Pembrolizumab (Keytruda) in first-line recurrent or metastatic head and neck squamous cell carcinoma, showing a 75% response rate and median progression-free survival of 10.9 months among 12 first-line patients. The combination also demonstrated a 42.9% response rate in second-line and later patients, compared to the typical 10-15% response rate for existing standard treatments in that setting. The company indicated plans to explore regulatory pathways including potential Breakthrough Therapy Designation based on these results.Investing.comTiumBio reports trial data for head and neck cancer drug By Investing.comTiumBio Co., Ltd. presented Phase 2a trial data for its drug candidate Tosposertib combined with pembrolizumab in recurrent or metastatic head and neck squamous cell carcinoma at the American Society of Clinical Oncology meeting, showing a 75% response rate and 10.9-month median progression-free survival in 12 first-line patients, with a 42.9% response rate in 14 second-line or later patients.Investing.comhttps://www.investing.com/news/company-news/tiumbio-reports-trial-data-for-head-and-neck-cancer-drug-93CH-4717958TiumBio presented Phase 2a trial data at the American Society of Clinical Oncology meeting for its drug candidate Tosposertib combined with pembrolizumab (Keytruda) in recurrent or metastatic head and neck squamous cell carcinoma. In first-line patients, the combination showed a 75% response rate with a median progression-free survival of 10.9 months, while second-line or later patients achieved a 42.9% response rate with 2.9 months median PFS. CEO Hun-taek Kim said the company plans to evaluate potential regulatory pathways, including seeking Breakthrough Therapy Designation.YahooTiumBio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First-Line R/M HNSCC at ASCO 2026TiumBio announced clinical data for Tosposertib (TU2218), an oral dual inhibitor, at ASCO 2026, showing a 75% response rate in first-line recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). The trial results indicated a median progression-free survival of 10.9 months, suggesting the combination may offer a clinical advantage over existing treatments. The data also showed promising response rates in later-line patients, with follow-up ongoing.PR NewswireTiumBio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First-Line R/M HNSCC at ASCO 2026TiumBio Co., Ltd. presented Phase 2a interim clinical data at ASCO 2026 showing that its oral dual inhibitor Tosposertib (TU2218) combined with pembrolizumab (Keytruda) achieved a 75% response rate and median progression-free survival of 10.9 months in first-line recurrent or metastatic head and neck squamous cell carcinoma patients. The combination demonstrated particularly strong efficacy in the high CPS subgroup (83% response rate) and showed meaningful activity even in second-line or later patients with a 42.9% response rate versus the historical standard of 10-15%. The treatment was generally manageable with 48.3% Grade 3+ treatment-related adverse events and no Grade 5 events or cardiovascular toxicities reported.GlobeNewswireHemophilia Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightDelveInsight released a hemophilia pipeline report covering 55+ drugs from 50+ companies, including Novo Nordisk, Roche, and Regeneron. Recent updates include Metagenomi's MGX-001 preclinical data and Novo Nordisk's FDA BLA for Denecimig. The report also highlights clinical trial data for NXT007 and other therapies.openPR.comEndometriosis Market: Rapid Growth & Investment Outlook to 2034 - DelveInsightDelveInsight's market report projects the global endometriosis market will grow from USD 2,300 million in 2023 with a significant CAGR through 2034, driven by rising disease prevalence and increased R&D investment. Key recent developments include NHS England's recommendation of the first long-term daily oral treatment (relugolix combination therapy) and positive Phase II results for Hope Medicine's HMI-115, alongside pipeline advancements from multiple companies including EndoCyclic Therapeutics, MSN Laboratories, and TiumBio. A setback occurred as Organon discontinued its drug candidate OG-6219 following a failed Phase 2 trial, after acquiring it through a $75 million deal for Forendo Pharma in 2021.